<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1557">
  <stage>Registered</stage>
  <submitdate>1/06/1996</submitdate>
  <approvaldate>1/06/1996</approvaldate>
  <actrnumber>ACTRN12607000025437</actrnumber>
  <trial_identification>
    <studytitle>IBCSG 15-95 - Randomised trial of high-dose epirubicin and cyclophosphamide x 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide x 4 followed by cyclophosphamide, methotrexate, and 5-fluoruracil x 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (&lt;=65 yrs) patients</studytitle>
    <scientifictitle>Randomised trial of high-dose epirubicin and cyclophosphamide x 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide x 4 followed by cyclophosphamide, methotrexate, and 5-fluoruracil x 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (&lt;=65 yrs) patients</scientifictitle>
    <utrn />
    <trialacronym>IBCSG Trial 15-95</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR130</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm B: Filgrastim (10ug/kg subcutaneously daily) for 6 days with leukapheresis on days 5-7. This is followed by 3 cycles (cycle =21 days) Epirubicin (200mg/m^2 iv over 12 hours on day 1), cyclophosphamide (4gm/m^2 iv as 4 divided doses  day 2), MESNA (7.2gm/m^2  days 2 &amp; 3), Peripheral Blood Progenitor Cell (PBPC) infusion (day 5) and Filgrastim (5ug/kg daily subcutaneously  from day 6 until White Blood Cells&gt;10 x 10^9/l). Tamoxifen (20mg orally daily) then follows for 5 years.</interventions>
    <comparator>Arm A: On day 1 of 4 cycles (cycle = 21 days) Epirubicin (90mg/m^2 iv) or Doxorubicin ( 60mg/m^2 iv) in combination with cyclophosphamide (600mg/m^2 iv) followed by 3 cycles (cycle = 28 days) cyclophosphamide (100mg/m^2 orally days 1-14), methotrexate (40mg/m^2 iv days 1 &amp; 8) and 5-Fluorouracil (600mg/m^2 iv days 1 &amp; 8) and then Tamoxifen (orally 20mg - daily) for 5 years.
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Followed 3 monthly during years 1  2, 6 monthly during years 3-5 and then annually until death.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Duration quality-adjusted time without symptoms and toxicity (TWiST and Q-TWiST)</outcome>
      <timepoint>Followed 3 monthly during years 1  2, 6 monthly during years 3-5 and then annually until death.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease-free survival and Systemic disease-free survival duration.</outcome>
      <timepoint>These secondary outcomes are followed 3 monthly during years 1  2, 6 monthly during years 3-5 and then annually until death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Toxicity</outcome>
      <timepoint>These secondary outcomes are followed 3 monthly during years 1  2, 6 monthly during years 3-5 and then annually until death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>These secondary outcomes are followed 3 monthly during years 1  2, 6 monthly during years 3-5 and then annually until death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost-effectiveness</outcome>
      <timepoint>These secondary outcomes are followed 3 monthly during years 1  2, 6 monthly during years 3-5 and then annually until death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Histologically proven breast cancer Primary tumour must be classified as T1a,b,c, T2 or T3, N1 or N2, M0 Patients must be categorized as at least one of the following:a) &gt;/= 10 involved axillary nodesb) &gt;/= 5 involved axillary nodes and primary tumour that is ER-negativec) &gt;/= 5 involved axillary nodes and T3 tumour who had breast cancer surgical procedure (irrespective of ER status) Attempts should be made to determine estrogen receptor status of tumour Patients must have had:a) Either total mastectomy or breast-conserving procedure (lumpectomy or quadrantectomy) for T1, T2 or T3 tumours.b) Primary breast cancer surgical procedure must be within six weeks prior to randomization Tumour must be confined to breast and axillary lymph nodes. All nodes must be examined by pathologist Left ventricular ejection fraction greater than 50% by resting MUGA radionuclide scan Adequate marrow function (WBC &gt;/= 4.0 x 10^9/l and platelet count &gt;/= 100 x 10^9/l) Adequate renal function (serum creatinine &lt;/= 120 mmol/l) and hepatic function (bilirubin &lt;/= 20 umol/l, AST (SGOT) &lt;/= 2 times the upper limit of normal) Informed consent Geographically accessible for follow-up ECOG performance status 0-2.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Malignant tumours other than carcinoma Locally inoperable breast cancer as defined by following:a) satellite skin nodules distant to primary tumourb) supraclavicular node involvementc) inoperable, matted axillary nodesd) primary tumour fixed to the chest wall, excluding pectoralis major Distant metastases Bilateral malignancies, or mass in opposite breast Other malignancies except basal cell carcinoma or carcinoma in situ of cervix Non-malignant disease preventing treatment options or prolonged follow-up Prior therapy for breast cancer Pregnant or lactating women Psychiatric, addictive or any disorder preventing informed consent Bone scan showing hot spots which cannot be confirmed as benign disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone or fax</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/1995</anticipatedstartdate>
    <actualstartdate>25/10/1995</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/03/2000</actualenddate>
    <samplesize>300</samplesize>
    <actualsamplesize>344</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress>Effingerstrasse 40, 3008 Bern</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australia and New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>PO BOX 155
HRMC NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australia and New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>PO BOX 155
HRMC NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical trial is for premenopausal and young postmenopausal women who after their breast cancer surgery have been found to have cancer cells in the glands of the armpit (positive axillary lymph nodes) and whose tumours do not have oestrogen receptors (are not stimulated by oestrogen). These tumour characteristics are often associated with a higher risk for breast cancer recurrence.

It is known that chemotherapy in standard doses after breast cancer surgery reduces the chance of breast cancer recurrence. However, this clinical trial aims to assess whether giving higher doses of chemotherapy is more effective in killing remaining cancer cells in women with a high risk of recurrence. Women will be allocated randomly (like the toss of a coin) to have either standard chemotherapy for their breast cancer, or high dose chemotherapy.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospita</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Hospital, Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/07/1995</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO Box 155
HRMC NSW 2310</address>
      <phone>+ 61 2 4985 0113</phone>
      <fax>+ 61 2 4960 1539</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+61 2 4985 0141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>